Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hospira Completes Acquisition of Orchid's Generic Injectable Unit | Contract Pharma

What are you searching for?

Sign in
Breaking News

Hospira Completes Acquisition of Orchid’s Generic Injectable Unit

Hospira, Inc. has completed the acquisition of the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., for approximately $400 million.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira, Inc. has completed the acquisition of the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., for approximately $400 million.

“We are excited to acquire new capabilities that will create opportunities for commercial growth, position us strongly in a key antibiotics product area, expand our global footprint and enhance our ability to provide lower-cost, high-quality products to patients,” said Terry Kearney, chief operating officer, Hospira. “We’re also excited to welcome a talented base of 450 employees, including newly appointed managing director, Hospira India, Dr. C.B. Rao, who joins us with a wealth of diversified industrial and management experience, and will provide continuity of leadership for the Orchid team joining Hospira.”

“Integration of Orchid’s injectables formulations business with Hospira, the global leader in generic injectables, represents a strong strategic fit. Our team is committed to leveraging our world-class infrastructure, high-technology product range and organizational competencies to drive even greater business growth and strengthen Hospira’s leadership position,” said Dr. Rao.

The acquisition includes Orchid’s beta-lactam antibiotic formulations manufacturing complex and pharmaceutical R&D facility in Chennai, India, as well as its generic injectable dosage-form product portfolio and pipeline. In addition, the companies have signed a long-term agreement for Orchid to supply APIs for the acquired generic injectable pharmaceuticals business.


Click here to learn more about Hospira

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics